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                              ABBREVIATIONS 
ACIOL   - Anterior Chamber Intraocular Lens 
BCVA    - Best Corrected Visual Acuity 
BRB      - Blood Retinal Barrier 
CME     - Cystoid Macular Edema 
DM       - Diabetes Mellitus 
ERG     - Eletroretinogram 
ECCE   - Extra Capsular Cataract Extraction 
FFA     - Fundus Fluorescein Angiography 
HT       - Hypertension 
ICCE   - Intra Capsular Cataract Extraction 
INL      - Inner Nuclear Layer 
IOP     - Intra Ocular Pressure 
IOL     - Intra Ocular Lens 
Nd YAG - Neodymium Yttrium Aluminium Garnet 
 NSAIDS - Non Steroidal Anti Inflammatory Drugs 
OCT       - Optical Coherence Tomography 
OPL       - Outer Plexiform Layer 
ONH      - Optic Nerve Head 
PCR      - Posterior Capsular Rupture 
PCIOL  - Posterior Chamber Intra Ocular Lens 
PST      - Posterior Sub Tenon 
PHACO - Phacoemulsification 
PMMA   - Poly Methyl Methacrylate 
PPV      - Pars Plana Vitrectomy 
RTA     - Retinal Thickness Analyser 
SLO     - Scanning Laser Ophthalmoscopy 
SICS   - Small Incision Cataract Surgery 
UV    - Ultraviolet 
 
                                        INTRODUCTION 
              Cataract represents global public health challenge for all countries. It still 
remains as the major cause of preventable blindness. Cataract surgery is the 
commonest surgery performed in the field of ophthalmology.   
                Among different surgical techniques performed for cataract, 
extracapsular cataract extraction (ECCE) / small incision cataract(SICS) surgery / 
Phacoemulsification with posterior  chamber intraocular lens implantation is the 
commonest one.  
               Despite these advantages, significant complication that can lead to visual 
impairment is cystoid macular edema. If steps are not taken properly to prevent, 
identify & treat cystoid macular edema,  it can be considered as 2
nd
 most common 
cause of preventable blindness next to cataract. 
  
        ANATOMY OF NORMAL MACULA 
            Macula lutea is situated in posterior  pole, centre of macula   is about 3 mm 
temporal to optic disc and 1 mm inferior to optic nerve head. Macula is 
approximately a circle with radius of 2.75 mm centered at fovea. Beginning at the 
centre, foveola is about 0.35mm diameter. In this region, rod cone ratio is 1:2. Its 
base is about 0.1mm diameter which is free of cells except outer segment of 
photoreceptors. 
          Fovea is 1.5mm diameter. Nerve fiber layer, ganglion cells, inner nuclear 
layer, inner plexiform layer are absent at fovea. Thickness of retina is 0.25 mm at 
the fovea. Fovea contains 10%of cones of whole retina. Cone density remains 
constant outside this region. Rods are absent in central 0.25mm of fovea. Capillary 
free zone is 0.4mm in diameter centered at fovea. 
         Parafoveal zone is an area measuring 0.5mm surrounding fovea. Rod cone 
ratio is 1:1 in this region. Rest of area is known as perifoveal zone. Macula lutea or 
yellow spot extends about 1mm laterally & 0.8mm above and below. 
              At the macula, ganglion cells are much more numerous than elsewhere in 
retina being arranged in several layers. Outer plexiform layer is also thicker than 
elsewhere, referred to as Henle’s layer.  Also, there is progressive disappearance of 
rods which are replaced by cones. Pigment epithelium layer & choriocapillaries are 
thicker at the macula which is significant because macula has no blood vessels. 
               Cone nuclei are heaped up in the fovea centralis but the remaining retinal 
layers are displaced laterally so that the internal limiting membrane which is very 
thin lies directly on the receptor nuclei. In the surrounding retina, nuclei of inner 
nuclear layer and ganglion layer increases in number, the volume contributing to 
raised rim of foveal depression. 
  In retina, each ganglion cell is connected to many visual cells, upto 100 
rods, whereas each cone is connected to only one ganglion cell. According to 
Wolffe, outer plexiform layer is made up of arborization of axons of the rods and 
cones with dendrites of bipolar cells. This layer also includes muller’s fiber and 
processes of horizontal cells. Elsewhere in the retina, this layer has a reticular 
structure, but takes a fibrous structure as macula is approached and is called Henle 
fiber layer. Fibers run vertically, then obliquely near the macula and finally parallel 
to the surface. This layer is thickest in the macula, but absent in fovea. This 
arrangement leads to accumulation of fluid in typical radiating petalloid pattern.  
Muller fibres are long complicated structures traversing the entire thickness 
of the retina from internal limiting membrane to external limiting membrane. 
Nucleus of  Muller fibre is bipolar and is situated at the level of inner nuclear layer. 
Floor of foveal center is rich in Muller fibres. 
 
 
 
 
 
 
 
 
 
 
         
 
 
DEFINITION OF CYSTOID MACULAR EDEMA 
Under normal conditions, internal and external blood retinal barriers 
separate retina from plasma by a system of restricted permeability. This ensures  
maintinenance of  homoestasis and a consistent internal milieu in the retina. When 
these barriers are disrupted due to any cause, there is increased entry of plasma 
constituents into extracellular space of the retina. Entry of plasma proteins and 
water causes expansion of the extracellular space, often associated with 
accumulation of fluid in the macular area which is called macular edema. 
 Macular edema may develop in inflammatory, occlusive,   degenerative, 
infiltrative, traumatic and toxic condition of retina, uveal tract, vitreous or even in 
some systemic diseases. 
Fluid accumulation in radially arranged fluid spaces localized to outer 
plexiform and inner nuclear layer of the para foveal retina is termed as cystoid 
macular edema (CME) 
 
              
          
 ETIOLOGY OF CYSTOID MACULAR EDEMA 
1. Associated with intraocular surgical procedure 
a. Cataract surgery with or without IOL implantation     (Irvine Gass 
syndrome) 
b. Cataract surgery with complications e.g., vitreous loss 
c. Aphakic keratoplasty  
d. Vitreous surgery  
e. Retinal surgery e.g, scleral buckling 
f. Retinal photocoagulation or cryotherapy 
g. Post surgical hypotony 
2. Associated with systemic and retinal vascular diseases  
a. Retinal vein occlusion 
b. Retinal telengiectasia  e.g.,coats disease, macular telengiectasia 
c. Radiation retinopathy 
d. Hypertensive retinopathy 
3. Associated with diabetes mellitus 
4. Associated with choroidal and retinal pigment epithelial disease 
a. Choroidal hemangioma 
 
 
b. Malignant melanoma 
c. Age related macular degeneration 
d. Retinitis pigmentosa 
e. Retinal pigment epitheliopathy 
f. Pseudo vitelliform dystrophy 
5. Associated with trauma or traction 
a. Idiopathic preretinal fibrosis 
b. Cellophane maculopathy 
c. Blunt ocular trauma 
d. Electric injuries to retina 
e. Solar retinopathy 
6. Associated with pathology of the vitreous 
a. Vitreous loss 
b. Vitreous adhesions to the wound 
7. Associated with uveitis  
a. Anterior uveitis e.g., non granulomatous iridocyclitis 
b. Intermediate uveitis or pars planitis 
c. Posterior uveitis e.g., behcet’s  disease 
 
 
8. Associated with drugs and pharmacological agents 
a. Nicotinic acid 
b. Topical epinephrine in aphakic eyes 
c. Oral contraceptive pills 
d. Hydrochlorthiazide 
e. Latanoprost, betoxolol, timolol 
 
 
 
 
 
            
 
       
 
 
 
        
  CLASSIFICATION  OF CYSTOID  MACULAR  EDEMA 
1. Based on visual acuity  
a. Angiographic CME 
      Refers to typical petalloid pattern of macular fluorescent 
leakage seen with fluorescent angiography but is not associated with 
decreased visual acuity. 
b. Clinical CME 
   It is associated with same macular pattern of fluorescent 
leakage on angiography with visual symptoms and a decrease in visual 
acuity of atleast two snellen lines or visual acuity worse than 20/40. 
2.  Based on severity of clinical course  
   a. Acute CME   resolves spontaneously in majority of   patients in six 
months following surgery. 
           b. Chronic CME when it persists for longer than six months, spontaneous 
resolution is less likely and is termed as chronic CME. 
 
      
                                      INCIDENCE 
 Despite major advances in cataract surgery techniques and instrumentation, 
CME
1,2
 continues to be one of the leading causes of decreased visual acuity after 
cataract surgery. The prevelance of CME after cataract  surgery depends upon 
experience of the surgeon, type of surgery, design of study, definition of disease , 
method for diagnosis, patient population, prior ocular surgery, coexisting ocular 
diseases, accompanying systemic diseases, surgical complications and follow up 
criteria. 
             Angiographic CME is very common and has been reported to occur in over 
50% of patients after cataract surgery with or without IOL implantation. But 
reduced visual acuity due to clinical CME occurs in upto 8% of patients. Incidence 
of pseudophakic CME also depends upon time lapse after surgery. It is highest 
44% in first six weeks postoperatively, 24% at six months and 12% at 12 months. 
It has been rarely reported after one year 
3
. 
 
 
 
   PATHOPHYSIOLOGY AND ETIOPATHOGENESIS 
            Although it still not clear, why fluid accumulates preferentially in foveal 
region despite widespread distribution of inflammatory mediators, several 
distinguishing features of the macula are thought to play a vital role. High 
metabolic activity, decreased fluid drainage, thin internal limiting membrane with 
less prevention of diffusion of inflammatory mediators, the thickness and 
horizontal course of outer plexiform layer providing a reservoir for fluid 
accumulation
4
.   
 BREAKDOWN IN BLOOD AQUEOUS BARRIER  
            Retina has barriers at 2 levels- retinal pigment epithelium and endothelium 
of retinal blood vessels. They have non leaking tight junctions. The blood aqueous 
barrier similarly has two barriers-tight junction of capillary endothelium in iris 
blood vessels  and posterior uveal lining of non pigmented epithelium.  
             The integrity of blood aqueous and blood retinal barrier can be assessed by 
slit lamp biomicroscopy (leakage of proteins and cells) or by fluorophotometry
5,6
 
(fluorescein concentration across these barriers into vitreous and aqueous). 
           Breakdown in blood aqueous barrier has been implicated as the prime cause 
of psuedophakic CME. There is breakdown in the functional complexes of the 
perifoveal capillaries allowing leakage of fluid and resultant edema. Miyake
7
 
suggested that the occurrence of CME is related to synthesis of prostaglandin and 
other mediators. Surgical trauma leads to release of prostaglandins which causes 
breakdown in the blood aqueous barrier with resultant release of toxins and 
immune complexes. 
          Prostaglandins pass through the vitreous into posterior chamber and result in 
outpouring of serous fluid in the henle’s layer. Increased levels of PGE& PGF 
have been demonstrated in patients with CME undergoing vitrectomy.  
       Therefore NSAIDS which inhibit the production of prostaglandin by blocking 
cyclooxygenase cycle are helpful in preventing as well as resolving CME after 
cataract surgery. 
 CHANGES IN THE VITREOUS 
              Changes in vitreous in the postoperative period may also play a role in  
etiopathogenesis. Vitreous cortex and vitreous face may serve as barriers for the 
diffusion of chemical mediators. However in cases with vitreous loss, anterior 
displacement of vitreous and increased vitreous liquefaction occurs. Even in 
uneventful surgery, during which no vitreous loss occurs, anterior displacement of 
it can occur after cataract surgery. 
Anterior displacement of the vitreous causes secondary changes in 
perifoveal vitreo-retinal interface, particularly in eyes in which spontaneous 
separation of the posterior hyaloid membrane has not occurred, playing a role in 
subsequent CME formation
8
. 
         Vitreous incarceration may also play a role in CME formation by causing 
mechanical vitreo-retinal traction on the perifoveal retina, thus changing the 
vascular permeability of   perifoveal retinal capillaries, leading to pooling of fluid 
in outer plexiform layer of retina. 
 
 
 
 
 
 
  
   HISTOPATHOLOGY OF CME 
           Histopathological studies
9
 of eyes with CME have shown   accumulation of  
water and proteinaceous materials causing marked swelling and edema with 
cystoid changes particularly of  outer plexiform  (henle’s ) layer and inner nuclear 
layer. 
            Electron microscopic studies of CME showed marked degeneration & 
swelling of muller cells with no enlargement of extracellular spaces which was 
described by Fine and Brucker
10
.  Gass and coworkers found polycystoid 
expansions of the extracellular spaces that correspond to the well developed pattern 
on CME on angiography. 
           Increased destruction of muller cell cytoplasm and necrosis of adjacent cells 
leads to formation of larger cystic spaces. Loss of photoreceptors is a consistent 
finding. 
           Wolter
11
 reported swelling of retina with formation of retinal folds, cystoid 
spaces in outer plexiform layer and inner nuclear layer and localized detachment of 
centre of macula in the area of external limiting membrane. In severe cases 
intraretinal hemorrhage with blood filled cysts may also occur. 
  
 ELECTRON MICROSCOPY 
            Fine and Bucker whose patients did not have well developed cystoid spaces 
on angiography found marked degeneration and swelling of the muller cells with 
no enlargement of extracellular spaces. Gass and coworkers found the polycystoid 
expansion of extracellular spaces that correspond to   the well developed pattern of 
CME on angiography. 
 
 
 
 
            
 
 
 
 
 CLINICAL FEATURES OF CME 
  SYMPTOMS 
1. Asymptomatic   
                       Angiographic PCME (psuedophakic cystoid macular                                        
edema)  is  usually  subclinical and transient . Majority of   patients belong to this 
category. 
2. Impairment of vision 
                     Generally occurs 1 to 4 months after cataract surgery.  There is mild   
to moderate drop in visual acuity. This visual acuity is usually about  6/18 or better  
and seldom  drop to less than 6/60. In patients with chronic CME, there is 
persistent visual loss. Reduced central vision,  metamorphosia, micropsia may be 
present. 
3. Loss of contrast sensitivity 
                Reduction in contrast sensitivity
12
 may occur in the presence of better 
visual acuity. 
 
 4. Acute delayed drop in vision 
                Rarely in cases with delayed PCME, patients  may  typically notice a 
sudden drop in their best corrected  visual acuity by 2 to 3 lines on the snellen 
chart. 
5. Symptoms of intraocular inflammation 
                 Rarely patients present with symptoms of uveitis like  pain, photophobia 
and an irritable eye. 
SIGNS 
               Clinical signs of CME are often mild and may be unnoticed unless there 
is a higher index of suspicion. Eye often appears normal as the anterior segment 
signs are very subtle. 
1. Mild ciliary flush and iritis 
             There may be mild ciliary flush along with iritis as is evidenced by flare, 
cells and mild anterior uveitis. 
2. Vitreous disturbance 
              A ruptured posterior capsule, cells in the anterior hyaloid  may be present. 
 3. Malpositioned IOL 
             This may cause pupillary distortion, iris tucking and iris chaffing. 
4. Fundus examination with I/O or 3 mirror contact lens 
            It reveals thickening and edema of the macula with honeycomb appearance 
due to the presence of microcystoid spaces. The cysts are bigger centrally with 
teardrop shape. They are best seen with retroillumination on the slit lamp. Foveal 
reflex is absent or distorted and cells may be seen in posterior vitreous. 
 
 
 
 
 
 
 
 
 
 
 RISK FACTORS FOR CME 
Absolute : 
1. Iris incarceration in wound 
2. Vitreous incarceration in wound 
3. Postoperative uveitis 
4. Postoperative vitritis 
5. Vitreous in anterior chamber 
6. Peaked pupil 
7. Posterior capsular rent 
8. Vitreous loss 
9. Post Nd YAG capsulotomy 
Relative: 
1. Young patients 
2.  CME in fellow eye 
3. Diabetes mellitus 
4. Systemic diseases 
          
   Absolute risk factors 
1. Iris incarceration in wound
13
 
Uveal tissue incarceration in the incisional site can result in chronic PCME. 
This condition often leads to persistent low grade iritis. This may be responsible 
for a prolonged breakdown in the blood aqueous barrier and thereby PCME. 
2. Iris IOL contact 
This may occur with the ciliary sulcus fixated IOL especially 10 degree 
angulated ones. PMMA haptics are more prone for uveal irritation. Malpositioned 
IOL’s can give rise to chronic uveal lens contact by causing pupillary distortion, 
iris tucking, iris chaffing, etc. This iris chaffing and capillary leakage result in 
breakdown of the blood aqueous barrier for long periods. Modern “in the bag” 
IOL’s which have no contact with iris have minimized CME as they produce least 
trauma to blood aqueous barrier
14
. 
3. Posterior capsular rupture 
Posterior capsular rupture especially if accompanied by vitreous loss has a 
greater predisposition for PCME
15
. This again is related to breakdown in the 
blood aqueous barrier and chronic inflammatory reaction propagated by this 
complication. Primary posterior capsulotomy performed during ECCE carried a 
significantly increased risk of CME
16
 than ECCE with intact posterior capsule. 
Also, angiographic PCME was found to be more common in primary post 
capsulotomy group than in those with intact capsule. Chronic uveitis set up by 
vitreous chaffing of the iris may be responsible in cases with associated vitreous 
disturbance. Thus it is evident that protective effect of posterior capsule is 
significantly negated by opening it. 
4. Postoperative uveitis 
This is important cause of PCME. Uveitis may be overt and marked with 
severe anterior chamber reaction. Commonly the eye may be apparently normal 
but careful examination often reveals mild ciliary flush,  few cells and flare in 
anterior chamber. Varying degrees of flare have been demonstrated by LASER 
flaremeter in cases of CME
17
. All complications associated with the risk of 
postoperative uveitis also increase the risk of PCME. These include excessive 
manipulation during intraocular surgery posterior capsular rent, vitreous loss, 
preexisting uveitis, preoperative pilocarpine usage , hypermature leaking cataract 
,uveal  incarceration ,IOL manipulation. Inflammatory mediators like PG’S & 
leukotrienes play a key role in such inflammation. 
 
 5. Phtotoxicity and operative microscope 
        Photic injuries have been described after surgical exposure to excessive  
illumination of the operative microscope. Byrnes GA et al 
18
 reported 10% 
incidence of such injuries. Spectral analysis of light source of the operating 
microscope have shown that measurable amount  of infrared and ultraviolet  light 
more of it being in the 500- 700nm range.  
6. Postoperative exposure to ultraviolet radiation 
 Besides photic injury during surgery, psuedophakic eye is also left 
unprotected from the external ultraviolet radiation after surgery.  Crystalline lens 
absorbs most of   incident UV radiation, thereby protecting the retina from a 
significant potential source of photic damage. This protection is lost when lens is 
removed. Implantation of IOL has ultraviolet absorbing  chromophobes 
incorporated in PMMA substance can possibly restore this protection. Thus a UV 
absorbing IOL besides restoring normal spectral sensitivity and reducing 
erythropsia, stabilizes blood vitreous barrier and reduces incidence of CME 
19
. 
  
 
   Probable risk factors 
1. Age   
Younger patients are more prone to develop CME
20
. Reason for this is more 
active immune system in young   which may be responsible in initiating the 
immune response to CME. 
2. CME in the fellow eye 
The incidence of clinically significant CME in the other eye when one eye 
has had this complication is reported to be high. Thus in a particular patients with 
CME, the second eye is considered as a prone eye. Prophylactic measures 
preoperatively (steroids or NSAIDS) have been recommended in such eyes 
21
. 
3. Diabetes mellitus 
Diabetics seem more prone to CME. Incidence of clinical CME among 
diabetics is reported as 9.3% and it’s average period of presentation to be 3 to 6 
months after surgery
22.
 Duration of diabetes, its severity, grade of retinopathy, 
general complications are important factors in the development of CME in 
diabetics. 
 4. Systemic diseases 
Patients with hypertension, cardiac disease, vascular diathesis, rosacea, 
telengiectasia, chronic alcoholism are reported to be at risk for developing CME 
20 
. 
 
 
 
 
 
 
 
 
 
 
                                    
 
INVESTIGATIONS 
Slit lamp examination with contact or noncontact lens makes it possible to 
detect presence of retinal thickening, whether localized or extending to posterior 
pole. Use of narrow slit beam is useful in detecting cystoid spaces. Clinical 
suspicion of macular edema can be confirmed with the aid of variety of 
investigations. Tests may be grouped into 3 categories according to whether one is 
analyzing the basic underlying pathogenesis, effect of macular edema on retina or 
its impact on visual function. 
A. Tests detecting disturbances in the blood retinal barrier  
Fundus flourescein angiogram( FFA) 
             .The typical angiographic finding described by GASS and  NORTON is 
the early dye leakage from perifoveal capillaries  followed by progressive filling of 
cystic spaces at later phases.  As the walls of the cyst don’t stain, a petalloid 
pattern is produced in the angiogram. The central ends of the petals seem to 
correspond to cysts in the outer plexiform layer while the peripheral ends of petals 
correspond to cysts in the inner nuclear layer. Late staining in the optic nerve is 
due to leaking capillaries in optic nerve head.    
Clinically, based on the flourescein leakage, five stage of PCME has been 
described.  
 Grade 0- no leakage 
 Grade 1- edema less than perifoveal area 
Grade 2- mild perifoveal edema 
 Grade 3- moderate perifoveal leakage about 1 disc diameter 
 Grade 4-severe perifoveal leakage of more than 1 disc diameter 
Side effects: 
1.  Extravasation and local tissue necrosis are the most serious complication 
which is very painful and may lead to subcutaneous nodule formation. This 
can be prevented by withdrawing blood into the syringe and scalp vein. 
   2.  Nausea, vomiting and allergic reactions 
   3.  Vasovagal shock 
   4.  Anaphylaxis – hypotension, tachycardia, bronchospasm,   itching 
    5.  Tonic clonic seizures, thrombophlebitis, pyrexia 
 
Characteristic feature of CME: 
A. Petalloid pattern of staining of cysts in macula 
B. Disc may leak or stain 
C. Leak into the vitreous in late phase  
 
B. Tests detecting retinal tissue thickening 
1. Optical coherence tomography(OCT) 
               OCT is a noninvasive device that obtains cross sectional    high resolution 
images of retina and thus may detect retinal thickening 
26
. It was infrared light to 
detect relative change in  reflection at optical interfaces by the method of low 
coherence interferometry. It may be thought of as being analogous to B scan USG, 
although it measures optical  rather than acoustic reflection. It is possibly indicated 
in early detection and follow up of patients with macular edema. It is as effective 
as fluorescein angiography but superior in detecting axial distribution of fluid. It 
measures the echo time taken for light to reflect from different structures at varying 
disturbances analogous to B scan ultrasonography. OCT examination is  indicated 
in early detection and follow up of patients with macular edema. It has been shown 
to have a high degree of reproducibility.  
 
2. Retinal thickness analyser(RTA) 
It is a rapid screening process which generates a detailed map of retinal 
thickening 
27
. The advantage of RTA is to scan a relatively wide area in a short 
time. 
3. Scanning laser ophthalmoscopy(SLO) 
It can quantify retinal thickness by ophthalmoscopy and retinal topography 
28
. It has been used to map retinal surface height revealing relative changes in the 
retinal surface height but not actual thickness. The axial resolution of SLO has 
been estimated at 300 micrometer   whereas the RTA has a claimed depth 
resolution of 50micrometer. The SLO measures changes at various depths and 
converts these into changes in 2 planes ie depth of retina whereas RTA measures 
the distance between 2 peak reflection on an angled laser slit into a measure of 
retinal thickness. It is a rapid and noninvasive imaging method that provides 
quantitative analysis of macular cysts in addition to qualitative information. 
Advantages of SLO is scanning a small  focused spot to generate an image , ability 
to image through small pupils, retinal hyperpigmentation, blood , heavy exudation 
or   subretinal fluid. It has been used to assess the   photoreceptor function in 
various stages of macular edema 
29
. 
 
C. Tests assessing retinal function 
       Macular edema may potentially affect the macular function as far as 
visual acuity and contrast sensitivity are concerned. Tests assessing macular 
functions may be used indirectly to detect the effects of macular edema and 
follow up its treatment. Contrast sensitivity and ERG are both clinical and 
experimental tools. 
1. Contrast sensitivity 
Ibanez et al in a prospective comparative study evaluated the effect of 
PCME on contrast sensitivity. They reported a statistically significant 
decrease in contrast sensitivity for patients who developed transient or 
persistent PCME for all spatial frequencies studied at 2 months and for 
higher frequencies at 8.5 months following surgery as opposed to no CME 
group. Reduction in contrast sensitivity may account for the persistent 
difficulties experienced by patients despite good snellen visual acuity 
30
.                 
2. Electroretinogram(ERG) 
      Regardless of the visual acuity, eyes with PCME show reduction in 
amplitude of the oscillatory potentials
12
 .This is said to be the most 
sensitive indicator of PCME. Oscillatory potentials are generated in the 
amacrine cells or inner plexiform layer and affected by any abnormality 
of the retinal vasculature. Analysis of each component of foveal ERG can 
be used to quantify the severity of PCME 
12
. 
TYPE 1: indicated by reduced amplitude of the oscillatory potential with 
normal a  and b waves. 
TYPE 2: characterized by reduced amplitude of oscillatory potential and 
b wave. 
TYPE 3: comprises reduced oscillatory potential and a  & b waves. 
 The mean time between cataract surgery and ERG changes was 
significantly longer for types 2 & 3 than for type 1. 
A very important development in the ERG-field in recent years is the 
multifocal-ERG recording system. This system allows assessment of ERG activity 
in small areas of retinal dysfunction and allows the derivation simultaneously of 61 
or 102 local ERG signals in a central visual field of about 60° diameter around the 
fovea in a considerably short time of 4 to 8 minutes. So the decrease or retinal 
function due to regional disorders in the outer retinal layers can be described in 
details by this technique, which allows the functional mapping of the retina. 
 
 
 
 
   MANAGEMENT OF CME 
   Management of CME includes the preventive measures to be taken and 
treatment which includes medical and surgical mode. 
    Preventive measures: 
    Although it is impossible at present to completely avoid PCME in all cases, 
a few precautions may prove important in reducing incidence and severity of 
this important postoperative complication. 
 Bag fixation of IOL 
 Use of PMMA IOL 
 Avoidance of primary posterior capsulotomy 
 Minimize microscopic light exposure 
 Minimize operation time 
 Use of UV filters and UV IOL 
 Prophylactic steroids in high risk factors 
 
 
 
 
 
1. Adequate suppression of preoperative uveitis 
Uveitis if present is treated by periocular and systemic steroids & a quiet 
period preferably for 3 – 6 months prior to surgery would be ideal. 
2. IOL surgery 
 Attention to finer details namely proper positioning of the IOL, avoidance 
of iris tuck and pupillary distortion helps in minimizing chances of PCME. In 
the bag placement of IOL is preferable. Operative manipulation is also kept to a 
minimum. 
3. Type of IOL 
PMMA IOL’s instead of 3 piece IOL’s with polypropylene haptics should be 
used. 
4. Posterior capsulotomy 
It should be avoided whenever possible. Even if required it should be 
delayed for upto 1 year postoperatively. 
 
 
 
5.  Adequate management of posterior capsular rent      
Especially if associated with vitreous loss. This includes complete clearance 
of vitreous from the anterior chamber. 
6. Adjustments in operating microscope 
Use of ultraviolet filters to reduce the phototoxic effect of   illuminating 
system in the operating microscope. 
7. Adjustments during surgery 
Several methods have been introduced to minimize the amount of light 
entering eye during surgery. Cornea is covered with a semiopaque material or filter 
or cellulose sponge. To block the light entering pupil during suturing and to 
minimize phototoxicity, insertion of IOL under air help to defocus the light. An air 
bubble may be placed in anterior chamber after IOL insertion as well as rotation of 
the eye 10 degree inferiorly by a superior rectus still helps to keep the illuminated 
image away from the fovea.  
8. Minimize operating time 
 Prolonged operating time besides exposing eye for a greater length of time 
to extraneous forces like instruments and infusion fluids, also increase the total 
dosage of phototoxic elements. Thus minimizing the operating time reduces the 
risk of prolonged blood aqueous barrier breakdown and photic inflammation which 
may predispose to CME. 
9. Use of UV absorbing  IOL 
 These have been used to prevent postoperative photic retinal damage and 
possibly CME. Komatsu et al 
31 
reported no statistically significant difference in 
visual acuity or incidence of CME on the basis of FFA performed 6 months 
postoperatively in patients with or without UV absorbing IOL’s. Kraff 19 reported a 
significant decrease in early postoperative angiographic CME with the use of UV 
filtering PCIOL’s. 
10. Use of prophylactic steroids & NSAIDS 
Use of topical prostaglandin inhibitors may prevent development of PCME 
21
. This is particularly useful in prone eyes such as in diabetics, those with uveitis 
in fellow eyes when the eye has had CME.  
                             
 
 
                                  
 
   TREATMENT                
Various models of treatment have been tried for CME. These include drugs 
like NSAIDS both topical and systemic, corticosteroids including oral, periocular 
and intravitreal, immunosuppressive, oral carbonic anhydrase inhibitors and 
vitrectomy, hyperbaric oxygen therapy and grid LASER photocoagulation. The 
challenge concerning the management of macular edema arises in chronic and 
persistent cases for which a stepwise approach is optimal. 
MEDICAL MANAGEMENT 
1. Topical NSAIDS and topical steroids 
32,33
 
Medical therapy for established PCME has focused primarily on use 
of anti-inflammatory drugs. Therapeutic blockage of prostaglandin and other 
chemical inflammatory mediators is the mainstay of management in CME. 
Topical NSAIDS are useful as they inhibit cyclooxegenase enzyme which is 
required for the production of prostaglandins.  Topical NSAIDS including 
ketoralac tromethanine 0.5%, diclofenac 1%, newer drugs like bromfenac 
and nepafenac 0.1% have been used either for the treatment of macular 
edema after cataract surgery 
32,33,34,35
 or prophylactically to prevent 
angiographic CME.  Weiz et al 
36
, suggested that the topical ketoralac 
eyedrops can be used with satisfactory results for the treatment of chronic 
PCME identified more than 24 months after cataract surgery.   
          Topical corticosteroids also inhibit production of prostaglandins by 
inhibiting the enzyme phospolipase A2 
37
. They penetrate the corneal 
epithelium and reach anterior chamber and are potentially helpful in treating 
CME caused by chronic iridocyclitis. More recently it has been reported that 
treatment of acute usually significant PCME with topical ketorolac & 
prednisolone combination therapy appears to offer benefits over monotherapy 
with either agent alone as their synergistic activity result in rapid resolution of 
symptomatic CME 
38
.  
      Side effects of NSAIDS include ocular irritation conjunctival irritation, 
punctuate keratopathy and mydriasis. Recently reports of corneal melting 
following administration of topical diclofenac have been established 
39,40.
       
       Side effects of topical steroids include glaucoma, posterior subcapsular 
cataract, exacerbations of infection & recurrence of herpetic keratitis
 41
. 
2. Corticosteroids 
a. Periocular 
The second step in the management of PCME is periocular steroids. Mc 
Cartney et al 
42
 used autoradiography to study penetration of hydrocortisone into 
both normal and inflamed eyes and found that the penetration was much faster in 
inflamed eyes. Injection can be given either as an orbital floor injection or as 
posterior subtenon injection.  
Posterior subtenon injection according to theory is more likely to be 
effective due to closer location of the drug to macula. Freeman et al 
43
, looked at 
the location of repository steroid injection using A and B mode ultrasonogram 
immediately before and after subtenon injection was given. They found that in 
57% of the injections given superotemporally and in 30% given infra temporally, 
there had been successful delivery of the drug to the macular region. 
Side effects:   Inadverent globe penetration, elevation of IOP, central retinal artery 
occlusion and cataract formation 
44,45
.  
b. Oral / systemic corticosteroids 
Very useful in treating inflammatory CME especially in bilateral or resistant 
cases. 
Side effects: Peptic ulceration, osteoporosis, exacerbation of diabetes mellitus , 
hypertension, cushingoid state and adrenal  suppression. 
 
 
 
 
 OTHER MODALITIES OF TREATMENT: 
1. Carbonic anhydrase inhibitors 
      These drugs act by increasing fluid absorption across the retinal pigment 
epithelium 
46,47
. They may alter the polarity of ionic transport systems in the retinal 
pigment epithelium through inhibition of carbonic andhydrase and gamma 
glutamyl transferase enzymes which inturn results in increased fluid transport 
across the pigment epithelium from the sub retinal space to choroid with the 
reduction of edema. Farber et al 
49
 studied 30 patients with CME secondary to 
chronic iridocyclitis and reported statistically significant visual improvement in 
group treated with acetazolamide. Response to treatment was better in younger 
than older individuals. Topical dorzolamide has also been used in the treatment of 
CME. 
     Grover et al 
50 
in the double masked cross over study reported that oral 
acetazolamide administered in 5 patients with retinitis pigmentosa was more 
effective than dorzolamide in managing chronic macular edema and improving the 
visual acuity and allows oxygen to diffuse from choroid to the inner retina , where 
it raises the oxygen tension and relieves hypoxia. Since no clinical trial has been 
done, there is no information available concerning its efficacy or safety.  
     
3. Hyperbaric oxygen 
    It is suggested that constriction of perifoveal capillaries by hyperbaric 
oxygen may facilitate the reformation of damaged functional complexes in the 
capillary wall resulting in decrease in macular edema. Oxygen may be beneficial in 
aphakic and pseudophakic macular edema or chronic CME attributable to uveitis
 
51
. 
SURGICAL TREATMENT 
A.   Intravitreal triamcinalone 
. Data in literature suggests that intravitreal triamcinolone  acetonide is a  
promising therapeutic method for chronic  pseudophakic CME resistant to medical 
treatment 
53,
. 
    Side effects - glaucoma, cataract, deposition of cortisone crystals in the macular 
region, transient central retinal artery occlusion, rhegmatogenous retinal 
detachment, endophthalmitis. 
      B. Nd YAG LASER vitreolysis 
           Lysis of vitreous strands to the cataract wound with Nd YAG LASER may 
have a role in treating CME after cataract surgery in a selective group of patients
54
. 
However many patients have extensive iridovitreal and iridocapsular adhesions 
that is not amenable to LASER vitreolysis. In addition risk of this treatment such 
as intraocular pressure elevation and retinal detachment should be considered 
carefully against the benefits. 
   C. Grid LASER photocoagulation 
         It was described as a method of treating CME using ruby and argon LASER 
photocoagulation
56
. Laser lesion in experimental animals shows a temporary 
breakdown of blood retinal barrier and a subsequent repair, as the retinal pigment 
epithelial cells adjacent to burns proliferate and slide to replace the necrotic cell. 
The new retinal pigment epithelial cells produce tight junctions in several weeks 
which restores the integrity of retinal pigment epithelial barrier
56
. An alternative 
hypothesis states that grid LASER by destroying photo receptors reduces the 
oxygen consumption of the outer retina and allows oxygen to diffuse from choroid 
to the inner retina where it raises oxygen tension and relieves hypoxia. 
D. Intra ocular lens removal 
         Some patients with IOL related CME (patients with iris clip IOL’s, rigid 
closed loop ACIOL, iris tuck by an IOL haptic  or capture of the iris by lens) may 
benefit from removal or exchange of IOL 
57
. 
 
E. Pars plana vitrectomy 
Mild cases of CME resolve spontaneously and many persistent cases 
respond to medical management. However in a minority of eyes clinical CME 
persists despite aggressive medical treatment. This is likely to occur in eyes with 
vitreous adhesions to the cataract wound and other anterior segment structures 
58,59
.  
Effect of vitrectomy in improving visual acuity in aphakic and pseudophakic 
eyes with chronic CME associated with vitreous incarceration to the cataract 
wound, adhesions to anterior segment structures or iris capture with posterior 
synechiae has been confirmed by several studies 
60,61,62
. Patients undergoing a 
complete pars plana vitrectomy have greater visual improvement than those 
undergoing a limbal vitrectomy 
61
.  
    The surgical procedure includes pars plana vitrectomy with complete 
removal of vitreous strands to the cataract wound and other anterior segment 
structures, lysis of irido vitreal and irido capsular adhesions. If no improvement 
occurs after several months of aggressive medical treatment, vitrectomy should be 
considered 
60
.    
      Peymen et al 
59
, reported pars plana vitrectomy with internal limiting 
membrane peeling and intra vitreal triamcinolone acetonide in two patients with 
chronic pseudophakic CME resulted in anatomical, angiographic and functional 
improvement. Additionally removing internal limiting membrane may allow better 
diffusion of intravitreally administered steroid to the macula. Vitrectomy is also 
beneficial in management of retained lens fragments
63
. 
      
 
    
            
 
 
                       
 
 
 
 
 
COMPLICATIONS OF CME 
1. Development of permanent retinal damage due to prolonged edema. 
2. Spontaneous rupture of the inner wall of a large central cystoid space to 
form a lamellar hole. Retinal pigment epithelium in the base of the hole is 
undisturbed. 
3. Cellophane maculopathy and macular pucker caused by epiretinal membrane 
may form either at the onset of CME or as a late complication of CME. 
When they occur it is less likely that visual acuity will return to normal even 
after the resolution of CME. Additionally, these membrane may peel 
spontaneously from the surface of the retina and good visual acuity is 
restored. 
4. Prolonged CME may occasionally produce atrophy of the outer retinal 
layers. Macula may appear normal except for absence of foveal reflex. 
 
 
 
     
                              
                                REVIEW OF LITERATURE  
         Although cystoid macular edema following cataract surgery is recognized as 
most common cause of decreased vision in post op period, reported incidence of 
this post -op complication continues to be quite variable. 
1. John R Wittpenn & Steven Silverstein 
65
(AMJ 2008 oct 146 issue 4 ) did a 
randomized masked comparison of topical ketorolac 0.5% with steroid 1% 
vs steroid 1% eyedrops alone in very low risk cataract surgery patients for 
CME. They concluded that adding perioperative ketorolac 0.5% to 
postoperative steroids significantly decreases the incidence of CME in 
patients without any known risk factors for CME.  
2. Keith A Walter & Amy J Estes 
66
 did a study on management of ocular 
inflammation following routine cataract surgery(US Opthalmic review 
2011 ;4-2 :97-100). The purpose was to determine whether bromfenac as a 
single agent is just as safe undergoing cataract surgery was done. 200 eyes 
were analysed in each group.1
st
 group received prednisolone 1% eyedrops 4 
times/day for 2 weeks & then tapered over 3 weeks.2
nd
 group received 
bromfenac 0.09% once daily 2weeks before surgery &4 weeks after surgery. 
They concluded that bromfenac is safe & as effective as topical steroid in 
controlling postoperative inflammation even when used alone without 
increasing intraocular pressure. 
3. CME in aphakic and pseudophakic eyes (AMJ ophthalmol.1979 july 88(1) 
: 45-8) was reported by Miami study group
67
. A prospective fluorescein 
angiography comparing the incidence of CME after intracapsular cataract 
extraction with implant, extracapsular cataract extraction with implant and 
intracapsular cataract extraction without implant was done. ECCE with 
implant and intact posterior capsule had a significantly lower incidence of 
CME than ICCE with implant surgery in 16 – 24 months post operatively. 
4. David L. Epstein 
68
 (AMJ ophthalmol.1977 Apr 83 (4) 501-3) reported 
incidence of CME 13 years after cataract surgery in a patient. Fluorescein 
angiography demonstrated CME except for vitreous adherence to the inner 
surface of cataract wound. No other cause was made out. 
5. Richard M. klein & Lawrence Yannuzzi
69
 reported the incidence of CME in 
first week after cataract extraction.  (AMJ Ophthalmol 1976  May 81(5) : 
614-5). They studied 100 consecutive cases of cataract extraction. 75 of 
hundred eyes demonstrated CME. They conclude that incidence of CME in 
1 st week after cataract surgery was low when compared to the reported 
incidence 4 – 6 weeks post operatively. 
6. Sanfold L. Severin reported the incidence of late onset CME in 
pseudophakia 
70
 ( AMJ Ophthalmol 1980 Aug ;90(2) : 223-5) after 1 year 
or more of cataract extraction. Out of 100 patients 3 patients developed 
CME, of which 1 patient resolved spontaneously and 2 patients did not 
resolve inspite of medical therapy. 
7. Rapid response of CME following Nd YAG LASER capsulotomy to 0.5% 
ketorolac tromethamine solution was reported by Michael S Lee & 
Jonanthan H Lass
71
 (Ophthalmic surgery lasers imaging 2004 Mar – 
April 35(2) 162-4) case report of 68 year old patient with CME following 
Nd YAG capsulotomy done for PCO was studied. Treatment with 0.5 % 
ketorolac eye drops had resulted in increase in visual acuity after 8 days of 
treatment and resolution of CME confirmed by FFA. 
8. Flash, Allan J et al.
72
 studied the effectiveness of ketorolac  tromethamine 
0.5% ophthalmic solution for chronic aphakic and pseudophakic CME(AMJ 
ophthalmol 1987 apr 15 ;103(4) 479-86).It was a double masked placebo 
controlled , randomized study which showed that the patients on ketorolac 
0.5% eye drops in treatment of aphakic and  pseudophakic macular edema 
had statistically proven significant improvement in visual acuity than those 
patients with placebo. 
9. Post cataract CME by Manish Nagpal, Kamal Nagpal et al.
73
, 
(Ophthalmology Clinics Of North America 2001 Dec p651-657) 
treatment with medical and surgical modes for CME was studied. Medical 
treatment includes topical periocular systemic steroids and topical NSAIDs 
and oral carbonic anhydrase inhibitors. Surgical treatment includes Nd YAG 
vitreolysis, Argon LASER photocoagulation, Pars Plana Vitrectomy. 
10. David S Rh et al 
74 – results of acute psuedophakic CME with diclofenac vs 
ketorolac was studied ( JCRS vol 29 (12) 2003 dec p 2378-84).This was a 
randomized prospective study of 34 consecutive patients with clinical CME 
after uneventful phaco with PCIOL. Eyes with CME treated with 1 drop 
diclofenac 0.1% eyedrops 4 times per day or ketorolac eye drops 0.5%. 
Outcomes measured by observing improvement of CME and vision. Both 
methods resulted in significant decrease in CME and increased vision. 
11. Chamblers William Stephens 
75
studied the incidence of CME after phaco 
(ophthalmology Vol 86(11) 1979 Nov p2019-2023). 1055 consecutive 
cases of phaco were studied. Results showed decreased incidence of CME if 
posterior capsule is left intact permanently. 
12. Heler, Jeffrey et al.
76
, studied monotherapy with ketorolac eye drops and 
prednisolone eye drops versus combined therapy in treatment of acute 
pseudophakic CME (ophthalmology vol 107 (11) 2000 Nov p2034-2038). 
28 patients after cataract surgery developed clinical CME in 21 to 90 days. 
They were given medical treatment. Results were combination therapy is 
better than monotherapy with ketorolac eye drops alone followed by 
prednisolone eye drops alone. 
13. Allan J.Flach 
77
 reviewed the incidence, pathogenesis and treatment of 
cystoid macular edema following cataract surgery (Trans American 
ophthalmology society-vol 96; 1998,p 557-634). He evaluated 7 laboratory 
and clinical studies to describe new information about the incidence, 
pathogenesis and treatment of CME following cataract surgery. 
14. Iliff W Jackson 
78
did a study on the phototoxic effect of relatively low 
intensity light on the retina and the suggestions by several authors that this 
might influence the development of CME in aphakic and psuedophakic 
patient [aphakic CME and the operating microscope- is there a 
connection; Trans Am Ophthalmol soc.1985;83;476-500). He suggested 
that operating microscope did not appear to be a significant factor in the 
development of CME but it represented a phototoxic threat to retina. 
15. CME following ECCE with PCIOL implantation by Bradford J David; 
Wilkinson and Bradford Jr Reagan.H 
79
(Retina – vol8; 1988- p 161-164). A 
retrospective review of 20 psuedophakic eyes with PCIOL and clinical CME 
was performed to compare the outcome of this macular disorder to that 
previously reported in both aphakic and psuedophakic eyes with 
iridocapsular or iris fixation IOL. Resolution of symptoms and apparent 
resolution of macular edema were observed in 18 cases. This study 
suggested that clinical CME occurring in association with PCIOL has a 
relatively fauvorable  outcome. Inflammation produced by iris manipulation 
and by chronic iris trauma associated with iris supported IOL was the most 
important factor. 
16. Jampol Lee M 
80
 (Archives of ophthalmology,1988 vol 106 p 894-895 ) 
did a prospective randomized clinical trial and concluded that there is 
increased incidence of CME in eyes that had undergone surgical 
capsulotomies than in those with eyes with intact posterior capsule. 
17. Ursell Paul G et al
 81
 reported CME after phacoemulsification              
(relationship to blood aqueous barrier damage and visual acuity JCRS 
vol 25 -11 1999 nov p 1492-1497). In this study , out of 100 patients 19 case 
had angiographic CME postoperatively. This study showed that after 
phacoemulsification with CCC, the incidence of CME appears to be similar 
to that after ECCE. 
18. Conway Mandi et al 
82
 did a non randomized retrospective study about 
Intravitreal triamcinolone acetonide for refractory chronic pseudophakic 
CME( J cataract refractive surgery 2003 jan vol 29 p 27-33 ). This was a 
study of 8 eyes of 8 patients with a history of psuedophakic CME 
recalcitrant to current standard treatment modalities. Mean duration of CME 
was 20 months. Patients received intravitreal injections of 1mg 
triamcinolone acetonide and were followed for 8 mon.  Visual acuity 
increased in all patients. Angiographic improvement occurred in all patients. 
19. Jost B Jonas, Kreissig and Robert F
 83
 reported (AJO 2003 vol 136 p 384-
386) reported the clinical outcome of intravitreal injection of triamcinolone 
acetonide as treatment of longstanding CME after phacoemulsification .The 
study included 5 patients who received intravitreal injection of 2.5 mg 
crystalline triamcinolone acetonide transconjunctivally with topical 
anaesthesia. All patients visual acuity improved but 2 patients developed 
increased IOP, which was controlled by antiglaucoma medications. 
20. A direct correlation of the resolution of psuedophakic CME with 
acetazolamide therapy was reported by Tripathi , Ramesh C et al 
84
(Annuals 
of ophthalmology vol 23-4 1991 april p 127-129). Acetazolamide probably 
increases the rate of absorption of subretinal fluid by inhibiting carbonic 
anhydrase & gamma glutamyl transferase enzyme in the retina and retinal 
pigment epithelium.  
21. Linda M Meyer & Carl Ludwig 
85
 (Case report ophthalmol 2011;2 p 319-
322) presented a case report. A 83 year old patient suffering from CME 
following cataract surgery in her left eye. She received 3 intravitreal inj of 
0.4mg dexamethasone in 3 months following cataract surgery without any 
improvement in visual acuity. 7 months after cataract surgery, she received a 
single intravitreal injection of 0.7mg dexamethasone. 4 weeks later, her 
visual acuity improved and CME resolved with decrease in retinal thickness 
on OCT from 390 microns to 212 microns after OZURDEX ( intravitreal 
dexamethasone implant).  
 
 
 
 
 
 
 
 
 
 
 
AIMS AND OBJECTIVES 
AIM: 
1. To study the clinical profile of CME following cataract surgery. 
2. To assess the response to various treatment modalities.                                                                                                                                                                       
 INCLUSION CRITERIA: 
           All cases of CME following cataract extraction. 
 EXCLUSION CRITERIA: 
1. Any known case of preexisting cystoid macular edema secondary to 
causes other than cataract extraction like uveitis with cystoid macular 
edema, diabetic macular edema.  
2. Prior intraocular surgery like trabeculectomy, retinal detachment and 
vitrectomy surgeries. 
3. Drug induced cystoid macular edema like latanoprost. 
4. Patients with any coexisting anterior segment or fundus pathology.                          
                 
 
 
MATERIALS AND METHODOLOGY 
           The study had been conducted at ophthal department of Government Rajaji 
Hospital, Madurai between February 2012 to October 2012. All patients diagnosed 
as having CME after cataract surgery were included in this study. Diagnosis of 
CME was by clinically identifying cystoid macular edema in the macular area 
using slit lamp biomicroscopy with 78D or 90D lens. FFA or OCT was done in all 
cases at the time of diagnosis and at each follow up to correlate the course of CME 
before and after treatment. 
INCLUSION CRITERIA: 
           All cases of CME following cataract extraction. 
 EXCLUSION CRITERIA: 
1. Any known case of preexisting CME secondary to causes other than 
cataract extraction like uveitis with cystoid macular edema, diabetic 
macular edema.  
2. Prior intraocular surgery like trabeculectomy, retinal detachment and 
vitrectomy surgeries. 
3. Drug induced cystoid macular edema like latanoprost. 
4. Patients with any coexisting anterior segment or fundus pathology.                          
METHODOLOGY: 
1. OCULAR HISTORY 
         Patient age, presenting complaints, duration of symptoms and mode of 
onset was taken. Review of medical records was done to identify preop, 
intraop and postop risk factors. 
2. SYSTEMIC HISTORY 
      Detailed history of diabetes mellitus and any other systemic illness was 
noted. 
       Detailed ocular examination including best corrected visual acuity, 
anterior segment and posterior segment examination by slit lamp 
biomicroscopy to intraop and postop risk factors for CME. 
a.  Visual acuity 
                       BCVA was measured by subjective and objective refraction with 
Snellen chart . 
b. SLE     
    SLE was carried out to look for  
 Any iris or vitreous incarceration at the wound site 
 Anterior chamber- cells and flare noted. 
Number of cells were assessed and graded from 0 to +4 as follows 
( HOGAN’S GRADING) 
<5          0 
5-10       1+ 
11-20     2+ 
21-50     3+ 
>50        4+  
             Aqueous cells are graded according to number observed in an oblique slit 
beam 3mm long and 1mm wide with maximal light intensity and magnification 
 Vitreous in anterior chamber 
 Posterior capsular rupture 
 PCIOL (in bag /sulcus) 
 Cells in the anterior vitreous  
Fundus illumination by slit lamp biomicroscopy with 90 lens: 
    All patients diagnosed as having CME were examined with slit lamp 
biomicroscopy using a noncontact lens after dilatation of pupil. Using thin angled 
slit beam, macula appears thickened with translucent intraretinal cystoid spaces 
which were best appreciated using red free light. Detailed fundus examination to 
rule out other causes of CME was also done.   
    
c.FFA  
    Inspite of a thorough fundus examination, diagnosis of CME cannot be 
established without the use of fundus fluorescein angiography which remains the 
gold standard for diagnosis. 
Detailed systemic examination were carried out for patients who 
underwent this procedure. Systemic side effects were explained to the patient and 
none of them experienced any serious adverse effect in our study. FFA was taken 
at the time of diagnosis and after treatment during subsequent follow up. 
 
 Procedure of FFA: 
Procedure of FFA was informed to the patient. The patient was kept nil 
orally for atleast 4 hours prior to FFA. Pupil was dilated. Red free photographs 
were taken. Scalp vein was inserted and 3ml of 20% flourescein dye was 
injected. Colour photographs were taken. After the FFA, patient was reassured 
about the red stained urine and patient was observed for atleast 20 min. 
 
 
c. OCT 
 OCT was done in patients wherever needed, at the time of diagnosis and 
after treatment during subsequent follow up. Macular thickness was measured at 
the time of diagnosis and after resolution of CME. 
d. Intraocular pressure 
IOP was recorded by goldmann applanation tonometer in patients who 
receive periocular and intravitreal steroids at the time of diagnosis of CME and 
during subsequent follow up.  
 
 
 
 
 
 
 
 
 
TREATMENT GROUPS 
          Patients were considered into 3 groups depending upon the visual 
improvement as follows 
GROUP A 
       Those patients whose visual acuity ranged from 6/6 – 6/18 were considered as 
group A.  They were treated with topical steroids   (prednisolone acetate 1% four 
times daily for 1 month) and topical NSAIDS (ketoralac tromethamine 0.5% four 
times daily for  1 month)& were followed up after 4 weeks. On follow up, IOP was 
measured in all patients and resolution of CME was noted. Those patients in whom 
CME did not resolve were treated as group B. 
GROUP B 
       Those patients whose visual acuity ranged from 6/24 – 6/36 were considered 
as group B and they were treated with periocular steroid injections. 
 
 
 
 
PROCEDURE OF POSTERIOR SUBTENON INJECTION 
4% lignocaine eyedrops applied every 5 minutes for 3 times with cotton 
tipped applicator, superotemporal quadrant was anaesthetized. Upper eyelid was 
retracted and patient was instructed to look down and nasally. With tuberculin 
syringe 30mg of triamcinolone acetonide was given. These patients were followed 
up after 4 weeks and IOP was measured. Patients who had raised IOP were treated 
with topical antiglaucoma medications. Resolution of CME was noted and those in 
whom CME was not resolved, repeat injections were given. 
GROUP C  
         Those patients whose visual acuity was <6/60 were considered as group C 
and treated with intravitreal steroids. 
PROCEDURE OF INTRAVITREAL STEROIDS 
        This procedure was performed under sterile conditions in OT using an 
operating microscope and topical anaesthesia. Lids and adnexa were cleaned with 
povidone iodine. Lid speculum applied and 4mg of injection triamcinolone 
acetonide was withdrawn in 1ml tuberculin syringe and was injected 
transconjunctivally at a distance of 3-3.5 mm from the limbus. Eye was examined 
immediately after injection for the presence of central retinal artery pulsations and 
those with impending obstruction underwent paracentesis. All eyes were 
reexamined at 15 minutes to half an hour after the injection to measure IOP and 
any immediate post injection complications. Patients were prescribed antibiotic 
eyedrops for atleast 3 weeks. 
       Patients were followed up after 2 weeks and IOP was measured and those 
patients whose IOP was high were treated with topical antiglaucoma drugs. They 
were followed up after 4 weeks and resolution of CME was noted.   
 
         
   
 
 
 
                 
 
 
 
TABLES AND GRAPHS 
TABLE 1: 
AGE DISTRIBUTION 
Age in Years No of patients Frequency 
<50 2 5% 
51 – 60 18 45% 
61 – 70 16 40% 
>70 4 10% 
Total 40  
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TABLE 2: 
GENDER DISTRIBUTION 
Gender Frequency Percentage 
Male 26 65% 
Female 14 35% 
Total 40  
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TABLE 3: 
DURATION FROM CATARACT SURGERY 
Duration Frequency Percentage 
4 – 6 weeks 22 55% 
7 -10 weeks 10 25% 
11 – 24 weeks 6 15% 
>24 weeks 2 5% 
Total 40  
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TABLE 4: 
TYPE OF CATARACT SURGERY 
Type Frequency Percentage 
ECCE with IOL 18 45% 
SICS with IOL 14 35% 
PHACO with IOL 8  20% 
Total 40  
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TABLE 5: 
TYPE OF IOL 
Type Frequency  Percentage 
PCIOL 38 95% 
ACIOL 2 5% 
Total 40  
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TABLE 6: 
SYSTEMIC ILLNESS 
Systemic illness Frequency Percentage 
DM 4 10% 
HT 4 10% 
Both 2 5% 
Nil 30 75% 
Total 40  
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TABLE 6: 
RISK FACTORS 
Risk factors Frequency Percentage 
Iris incarceration in Wound 2 5% 
Vitreous in AC 2 5% 
PCR 6 15% 
Uveitis 18 45% 
Vitritis 12 30% 
Total 40  
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TABLE 8:  
PRE- TREATMENT BCVA 
Pre treatment BCVA Frequency Percentage 
6/6 – 6/18 22 55% 
6/24 – 6/36 12 30% 
< 6/60 6 15% 
Total 40  
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TABLE 9:  
FINAL BCVA 
Final BCVA Frequency Percentage 
6/6 – 6/18 33 88.3% 
6/24 – 6/36 5 8.4% 
< 6/36 2 3.3% 
Total 40  
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TABLE 10: 
TREATMENT MODALITIES 
Treatment modalities Frequency Percentage 
Topical NSAIDS & Steroids 22 55% 
Periocular steroids 12  30% 
Intra vitreal steroids  6 15% 
Total 40  
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TABLE 11: 
RESOLUTION OF CME 
Resolution of CME Frequency Percentage 
Resolved 35 87.5% 
Not Resolved 5 12.5% 
Total 40  
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TABLE 12:  
TOPICAL VS PERIOCULAR VS INTRAVITREAL STEROIDS FOR 
TREATMENT OF CME 
Treatment given Topical NSAIDS & 
Topical steroids 
Periocular 
Steroids 
Intravitreal 
Steroids 
No of patients 22 12 6 
Resolved 14 (64%) 9 (75%) 4 (67%) 
Not Resolved 8 (36%) 3 (25%) 2 (33%) 
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TABLE 13:  
INCREASING IOP ON FOLLOW UP 
Increasing IOP Frequency Percentage 
Yes 7 17.5% 
No 33 82.5% 
Total 40  
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  DISCUSSION 
     CME after cataract surgery is the most common cause of decreased 
vision in the postoperative period. This clinical condition was first 
recognized by IRVINE in the year 1953 and now this condition is known as 
IRVINE GASS SYNDROME. 
  Most of the patients in our study developed CME in 4-6 weeks (55%). 
CME was most common in ECCE with IOL (45%) than SICS with IOL 
(35%) than PHACO with IOL (20%). 
      The most important intraoperative risk factor includes posterior capsular 
rupture associated with vitreous loss which cause breakdown in blood 
aqueous barrier and chronic inflammatory reaction. In our study, 6 patients 
had posterior capsular rupture as intraoperative complication in which 3 eyes 
with CME was not resolved due to formation epiretinal membrane, macular 
hole and macular degeneration. 
In our study, major post operative risk factor include uveitis(18%) and 
vitritis (12%). These factors indicate that inflammatory mediators like 
prostaglandins and leukotrienes play a key role to cause post operative CME. 
All patients were examined by slit lamp biomicroscopy with 90D lens 
and FFA was done in all patients at the time of initial diagnosis and 
subsequent follow up which showed resolution of CME after treatment. 
As OCT is a noninvasive device, which obtains high resolution images of 
the retina and detects the presence of retinal thickening and it causes 
minimal discomfort to the patient, OCT was done in all cases at the time of 
diagnosis, at each follow up visit which showed resolution of CME and 
decrease in macular thickness after treatment. 
     Flanch Allan et al
72
  had done a double masked placebo controlled 
randomized study in 1987 which indicated that ketorolac 0.5% eyedrops in 
aphakic and pseudophakic patients with macular edema showed that 
statistically significant visual acuity improvement than those patients with 
placebo. 
        As per Jeffrey et al study
76
, combination therapy of ketorolac and 
prednisolone eyedrops in acute CME, who had done a randomized double 
masked prospective trial of 28 patients who developed clinical CME after 
21-90 days postoperatively. Patients experienced recovery of 2 or more lines 
of visual acuity after combination therapy. They concluded that combination 
therapy appears to offer more benefit than monotherapy.  
      More recently, it has been reported that treatment of acute, visually 
significant PCME with topical ketorolac and prednisolone combination 
therapy appears to offer benefits over monotherapy with either drug alone as 
their synergestic effort results in rapid resolution of CME after treatment. 
In our study, 22 patients presented with CME between 4-6 weeks postop 
period whose visual acuity range from 6/6- 6/18 was treated with 
administration of topical ketorolac tromethamine 0.5% eyedrops 4times per 
day for 1 month and topical steroids 1% eyedrops for 1 month. 14 patients 
showed resolution of CME at 1
st
 follow up (i.e.) after 4 weeks. In remaining 
8 patients CME was not resolved and they were treated with periocular 
steroids (i.e.) posterior subtenon injection of triamcinolone acetonide 30mg. 
CME was resolved in 8 cases and in 2 cases visual acuity did not improve 
due to macular degeneration. 
2
nd
 step in the treatment of postop CME is periocular steroids. According 
to Mccartney et al, injection triamcinolone acetonide 40mg given as 
posterior subtenon injection is more likely to be effective due to closer 
location of drug to the macula. 
In our study, 12 patients who presented with CME between 4-6weeks 
postop period whose visual acuity range from 6/24-6/36 was treated with 
posterior subtenon injection triamcinolone 30mg. Out of 12 patients, 9 of 
them showed resolution of CME in 1
st
 follow up(i.e.) after 4 weeks. In 3 
patients, CME was not resolved and they were given repeat triamcinolone 
30mg by posterior subtenon route. At the final follow up also, these 3 
patients did not show improvement in visual acuity due to formation of 
epiretinal membrane, macular hole and macular degeneration. And they 
showed increased IOP in the range of 24-28mm Hg and were treated with 
timolol 0.5%eyedrops twice daily. 
3
rd
 step in treatment of CME is intravitreal triamcinolone acetonide. 
Conway mandi et al
82
 had done randomized retrospective study about 
intravitreal triamcinolone acetonide for refractory chronic PCME. A study of 
8 eyes of 8 patients with history of PCME recalcitrant to current standard 
treatment modalities. Patients received intravitreal injection of 1mg 
triamcinolone acetonide and were followed up for 8 months. Visual acuity 
was increased in all patients and there were temporary increase in IOP which 
were easily controlled with topical antiglaucoma drugs. 
In our study, 6 patients whose visual acuity was <6/60 were treated with 
injection intravitreal steroids (i.e.)intravitreal triamcinolone acetonide 4mg. 
They were reviewed after 2 weeks and complication like raised IOP was 
noted in 3 patients. And they were reviewed after 4 weeks and resolution of 
CME was noted. Out of 6 patients, 4 of them showed resolution of CME and 
in 2 patients CME was not resolved due to chronic CME. 
4
th
 step in management of CME is pars plana vitrectomy. In our study, 
none of the patients underwent PPV. William Harton et al  
reviewed 24 consecutive cases who underwent PPV in 1 eye for PCME. All 
24 patients failed to improve on medical therapy and had preop evidence of 
either vitreous adhesion to anterior segment structures or iris capture with 
IOL. 17 patients experience 3 or 4 lines of postop visual acuity improvement 
and all 24 patients had atleast 1 line improvement. 
In our study, out of 40 patients 5 patients CME was not resolved even at 
the final follow up. Of which 3 patients who had posterior capsule rupture 
associated with vitreous loss as an intraoperative complication and they had 
uveitis postoperatively and they were treated with periocular steroids at the 
time of diagnosis of CME and they were reviewed after 4 weeks, since CME 
was not resolved, the injection was repeated. At the final follow up also, 
CME was not resolved due to formation of epiretinal membrane, macular 
hole and macular degeneration. 2 patients who had zonular dialysis as an 
intraoperative complication and they had uveitis and vitritis postoperatively 
and they were treated with intravitreal steroids. CME was not resolved due 
to chronic CME. 
  Out of 40 patients, 7 patients showed raised IOP after 4 weeks of 
treatment. Out of 7 patients, 2 of them who received posterior subtenon 
injection once and 2 patients who received  posterior subtenon injection 
twice showed raised IOP in the range of 24-28mm Hg and 3 patients who 
received intravitreal steroids showed raised IOP  in the range of 28-30mm 
Hg. All these patients were treated with topical 0.5% timolol eyedrops 
twice daily and their IOP were under control. 
 
 
 
 
                          
 
 
 
                                  SUMMARY 
 Our studies included 40 patients with CME following cataract surgery with 
IOL of which 38 patients (95%) were implanted with PCIOL and 2 patients 
(5%) with ACIOL. Out of 40 patients 26 (65%) were men and 14 (35%) 
were women. 
 22 patients (55%) developed CME in 1
st
 4-6 weeks postoperative period 
and 10 patients (25%) in 6-10weeks and 6 patients (15%) developed CME 
after 11-24 weeks and 2 patients (5%) developed CME after 24 weeks. 
 18 patients with CME underwent ECCE with IOL (45%), 14 underwent 
SICS with IOL (35%) and 8 patients underwent PHACO with IOL (20%). 
 Among systemic diseases, 4 patients had Diabetes mellitus, 4 patients had 
Hypertension, 2 patients had both diabetes and hypertension. 
 Among 40 patients, none of the patients were treated with preop topical 
NSAIDS for preop uveitis. 4 patients were found to have CME in fellow 
eye. 
 Among 40 patients, 6 patients (15%) had posterior capsular rupture 
associated with vitreous loss intraoperatively and had PCIOL implantation 
after anterior vitrectomy. 
 Among 40 patients, 2 patients had ACIOL implantation due to >180 degree 
zonular dialysis. 
 Postoperative examination revealed 18 patients (45%) had uveitis, 12 
patients (30%) had vitritis, 2 patients (5%) had iris incarceration in wound. 
2 patients (5%) had vitreous in anterior chamber. 
GROUP A: 
In our study 22 patients whose visual acuity range from 6/6 -6/18 were 
considered as group A.  Mean pretreatment visual acuity was 6/13.  Mean 
pretreatment macular thickness was 340microns.  
  They were treated with topical steroids (prednisolone 1% eyedrops 4 times 
daily for 1 month) and topical NSAIDS (0.5% ketolorac eyedrops 4 times daily for 
1 month) at initial diagnosis of CME. 
   These patients were reviewed after 4 weeks and their IOP was measured by 
Goldmann applanation tonometer. Out of 22 patients, 14 patients showed 
resolution of CME. Their mean post treatment visual acuity was 6/9.2. Their mean 
post treatment macular thickness was 250 microns. 
  In 8 patients, CME was not resolved with topical steroids and topical 
NSAIDS. They were treated with periocular steroids (triamcinolone acetonide 
30mg by posterior subtenon route). These patients were reviewed after 4 weeks. 
CME was resolved in all 8 patients both clinically and by OCTwise. 
  6 patients showed visual acuity improvement by 1 to 2 lines and in 2 patients 
visual acuity remained the same. Macular degeneration is the cause for non 
improvement of visual acuity in these cases. 
In one patient, IOP was high level (26mmHg) and patient was treated with 
0.5% timolol maleate eyedrops two times per day. 
 GROUP B: 
12 patients whose visual acuity ranged from 6/24 – 6/36  were considered as 
group B. Mean pretreatment visual acuity was 6/26 and pretreatment macular 
thickness was 480microns. They were treated with periocular steroids (posterior 
subtenon injection of triamcinolone acetonide 30mg). Before giving periocular 
steroids, IOP was measured. 
These patients were reviewed after 4weeks. Out of 12 patients, 9 patients 
showed resolution of CME. Mean post treatment visual acuity was 6/30 and mean 
post treatment macular thickness was 300microns. IOP was measured in the 1
st
 
follow up. In 3 patients, CME was not resolved and they were treated with repeat 
posterior subtenon injection. At the final follow up also, these 3 patients did not 
show improvement in visual acuity due to epiretinal membrane, macular hole and 
macular degeneration. They showed raised IOP in the range of 24-28mmHg and 
were treated with 0.5% timolol eyedrops two times per day. 
GROUP C; 
6 patients whose visual acuity was <6/60 were considered as group C. Their 
mean pretreatment visual acuity was 6/120 and pretreatment macular thickness   
was 780microns. 
Since they presented with significant CME, they were treated with 
intravitreal steroids (triamcinolone acetonide 4mg). Before giving injection, IOP 
was measured. 
They were reviewed after 2 weeks and complications like raised IOP noted 
and again reviewed after 4 weeks and resolution of CME was noted. 
Out of 6 patients, 4 patients showed resolution of CME and in 2 patients 
CME was not resolved. Their mean post treatment visual acuity was 6/80 and 
mean post treatment macular thickness was 350microns. 2 patients visual acuity 
got worsened and the reason was due to chronic CME. 3 patients showed raised 
IOP in the range of 28-30mm Hg and were treated with timolol 0.5% eyedrops 
twice daily. 
 
                                    CONCLUSION 
 In our study, CME was the most common vision threatening complication 
following cataract surgery who presented with defective vision in 1
st
 4-6 
weeks postoperatively. 
 Periocular steroids were found to be most effective form of treatment.  
 Topical NSAIDS and topical steroids were also effective in treating 
Psuedophakic cystoid macular edema and intravitreal steroids can be given 
in resistant cases. But periocular and intravitreal steroids most commonly 
associated with raised IOP compared to topical steroids. 
  Other modalities of treatment like pars plana vitrectomy and grid laser 
photocoagulation should be considered in resistant cases.   
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                                                         PROFORMA: 
Name :        Date : 
Age :       OP/IP no: 
Sex :  1. Male       Eye :   1.Right            
             2.Female            2.Left  
Address : 
  
 Duration from cataract surgery                                
 Date of surgery : 
1. 4 – 6 weeks 
2. 7 – 12 weeks 
3. 12 – 24 weeks 
4. > 24 weeks 
 Type of cataract surgery   
1. ECCE with IOL 
2. SICS with IOL 
3. PHACO with IOL 
 
 Type of IOL  
1. PCIOL 
2. ACIOL 
 Preoperative risk factors 
A. Systemic illness  
1. Diabetes mellitus   2. Hypertension    
3. Both         4. No 
    B.  Treatment for post operative uveitis            
                                       1. Yes    2. No 
C. Pre-op use of topical NSAIDs          
                 1. Yes    2. No 
D. CME in other eye              
                1. Yes    2. No 
 Intraoperative complications  
a) PC rupture              1. Yes    2. No 
b) If yes, Vitreous loss                    1. Yes    2. No 
c) Vitrectomy done            1. Yes    2. No 
 
 d) PCIOL Placement                    1. In bag            
                                                                          2. In sulcus 
e) Type of IOL             1. PCIOL   
                                                   2. ACIOL                                                                   
 Post –op examination 
1. Visual acuity  
Unaided  
BCVA  
  Anterior segment examination 
2. Uveitis       1. Yes    2. No 
3. Vitritis      1. Yes    2. No 
4. Other findings                                        1.Yes     2. No 
a. Iris incarceration in wound 
b. Vitreous incarceration in wound 
c. Vitreous in AC 
d. Peaked pupil 
e. PC rent 
 
Posterior segment examination  
Slit lamp examination with 90 D lens 
1. CME                  1. Yes    2. No 
2. Clinical vitreomacular traction               1. Yes    2. No 
3. Other findings  
1. Epiretinal membrane 
2. Macular hole 
3. Serous retinal detachment 
4. Diabetic retinopathy 
5. Hypertensive retinopathy 
6. Central retinal vein occlusion 
7. Branch retinal vein occlusion 
8. Nil 
 
Treatment given:   
1. Topical steroids & topical NSAIDs 
2. Periocular steroids 
3. Intra vitreal steroids 
4. Pars plana vitrectomy 
  FOLLOW UP 
                 Name                  :     MRD No  : 
                 Date       : 
                Vision   1.Unaided  
                                2. Best corrected visual acuity 
Anterior segment examination 
1. Uveitis     :   yes /no 
2. Vitritis     :   yes / no 
Tension  ( by applanation  tonometer)   : 
Treatment with timolol      :  yes / no 
Fundus  
 CME resolved     
 1. Clinically by slit lamp 90 D :  yes / no 
 2. By FFA               :  yes / no 
 
 
Treatment given 
 1. Topical NSAIDs 
 2. Periocular steroids 
 3. Intra vitreal steroids 
 4. Pars plana vitrectomy 
 
                     RISK FACTORS FOR CME 
                    
                   ACIOL 
 
     POST Nd YAG CAPSULOTOMY 
 
 
 POST OP UVEITIS  
 
PC RUPTURE 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
ANATOMY OF RETINA 
 
 
 
 
 
OCT IMAGE OF NORMAL RETINA 
  
 
 
HISTOPATHOLOGY OF CME 
 
 
Slit lamp biomicroscopy showing CME
FFA in early phase showing 
cystoid spaces
 
 
 
FFA  in late phase showing flower petal 
appearance of CME 
 
Spectral domain OCT showing CME
 
SD OCT
Cystoid spaces in the outer
plexiform layer
 
 
 

S.No Patients Name Age Sex IP No
Systemic 
Disease
Preop BCVA Postop BCVA Procedure Done Risk factors for CME
CME Diagnosed 
in weeks
Treatment 
Given
Additional 
Treatment
BCVA improved 
after Treatment
BCVA after 
Treatment
IOP Rise 
after 
Steroids
Antiglaucoma Drugs
1 Vinayagam 62 M 81283 No 6⁄60 6 ⁄24 ECCE WITH PCIOL PCR AND VL 4 to 6 Gp B Rpt PST No 6 ⁄24 yes given
2 Rajalakshmi 52 F 81300 No 6⁄ 60 6 ⁄36 SICS WITH PCIOL Vitritis 7  to10 Gp B No yes 6 ⁄12 no no
3 Chokkalingam 64 M 81365 DM 5 ⁄60 6 ⁄60 ECCE WITH PCIOL PCR AND VL 4 to 6 Gp C No yes 6 ⁄36 no no
4 Ramasamy 51 M 81378 No 6 ⁄36 6 ⁄12 PHACO WITH PCIOL Uveitis 11 to 24 Gp A No yes 6⁄ 6 no no
5 Selvaraj 53 M 81465 HT 6⁄60 6⁄ 24 SICS WITH PCIOL Vitritis 7 to 10 Gp B No yes 6 ⁄12 no no
6 Ammapillai 65 F 81488 No 5 ⁄60 6 ⁄60 ECCE WITH PCIOL Vitreous in AC 4 to 6 Gp C No yes 6 ⁄24 no no
7 Chinnasamy 55 M 81505 No 6 ⁄36 6⁄ 12 PHACO WITH PCIOL Uveitis 11 to 24 Gp A No yes 6 ⁄9 no no
8 Yasodha 61 F 81512 DM 6 ⁄60 6 ⁄24 ECCE WITH PCIOL Uveitis 4 to6 Gp B No yes 6 ⁄9 no no
9 Karupasamy 72 M 81289 No 3 ⁄60 4 ⁄60 E CCE WITH ACIOL Zonular dialysis 4 to 6 Gp C No No 4 ⁄60 no no
10 Saroja 64 F 81536 DM 6⁄ 36 6 ⁄24 ECCE WITH PCIOL Vitritis 7  to 10 Gp B No yes 6⁄ 9 no no
11 Rasupillai 58 M 81356 No 6 ⁄36 6⁄ 12 PHACO WITH PCIOL Uveitis 4 to 6 Gp A No yes 6⁄ 6 no no
12 Lakshmi 54 F 81653 No 6 ⁄60 6⁄ 24 ECCE WITH PCIOL Vitritis 7 to10 Gp B No yes 6⁄ 12 no no
13 Velu 63 M 81699 No 6 ⁄60 6 ⁄18 SICS WITH PCIOL Uveitis 7 to10 Gp A PST inj yes 6 ⁄9 no no
14 Sundaram 52 M 81680 HT 6 ⁄36 6⁄ 9 SICS WITH PCIOL Uveitis 7 to10 Gp A No yes 6 ⁄6 no no
15 Shanthi 74 F 81735 No 3 ⁄60 6 ⁄60 ECCE WITH PCIOL Uveitis 4 to 6 Gp C No yes 6 ⁄24 yes given
16 Raju 67 M 81795 No 6 ⁄60 6 ⁄24 SICS WITH PCIOL Vitritis 4 to 6 Gp B No yes 6⁄ 9 no no
17 Kamatchi 55 F 81864 No 6 ⁄60 6 ⁄9 ECCE WITH PCIOL Uveitis 4 to 6 Gp A No yes 6 ⁄6 no no
18 Subbiah 69 M 81899 DM 4⁄ 60 6 ⁄24 SICS WITH PCIOL PCR AND VL 4 to 6 Gp B No yes 6⁄ 12 yes given
19 Murugan 57 M 82301 No 6 ⁄60 6 ⁄18 SICS WITH PCIOL Vitritis 4 to 6 Gp A PST inj yes 6⁄ 9 no no
20 Subbamaal 65 F 82355 No 6 ⁄60 6⁄ 12 ECCE WITH PCIOL Uveitis 7 to10 Gp A No yes 6⁄ 6 no no
21 Marimuthu 71 M 82467 No 5⁄ 60 6 ⁄60 SICS WITH PCIOL Vitritis 4 to 6 Gp C No yes 6⁄ 24 yes given
MASTER CHART
22 Kesavan 58 M 82543 HT 6 ⁄36 6 ⁄18 ECCE WITH PCIOL Vitritis 7 to10 Gp A PST inj yes 6⁄ 9 no no
23 Pitchai 66 M 82678 No 5⁄ 60 6 ⁄36 PHACO WITH PCIOL PCR AND VL 4 to 6 Gp B No yes 6⁄ 12 no no
24 Vijayalakshmi 54 F 82877 No 6 ⁄24 6 ⁄9 ECCE WITH PCIOL Uveitis 11 to 24 Gp A No yes 6 ⁄6 no no
25 Rajendran 52 M 82885 HT 6 ⁄24 6⁄ 12 ECCE WITH PCIOL Uveitis 11 to 24 Gp A No yes 6 ⁄9 no no
26 Sekar 62 M 83193 No 6 ⁄60 6 ⁄12 SICS WITH PCIOL Uveitis 7 to10 Gp A No yes 6⁄ 6 no no
27 Jebaraj 55 M 83243 No 6 ⁄60 6⁄ 18 ECCE WITH PCIOL Vitritis 4 to 6 Gp A PST inj yes 6 ⁄9 no no
28 Manikandan 59 M 83367 No 6 ⁄36 6 ⁄12 SICS WITH PCIOL Vitritis 4 to 6 Gp A No yes 6⁄ 9 no no
29 Maanickam 68 M 83452 No 6 ⁄60 6⁄ 24 ECCE WITH PCIOL Vitreous in AC 4 to 6 Gp B No yes 6⁄ 9 no no
30 Sundari 49 F 83532 No 6 ⁄36 6 ⁄12 SICS WITH PCIOL Uveitis >24 Gp A No yes 6⁄ 9 no no
31 Perumayee 69 F 83566 Both 6 ⁄60 6 ⁄18 ECCE WITH PCIOL Uveitis 4 to 6 G p A PST inj yes 6⁄ 12 yes given
32 Rengasamy 52 M 83612 No 6 ⁄36 6⁄ 18 PHACO WITH PCIOL Vitritis 7 to10 Gp A PST inj yes 6 ⁄9 yes given
33 Chinnaperukki 75 F 83722 No 3 ⁄60 5 ⁄60 ECCE WITH ACIOL Zonular dialysis 4 to 6 Gp C PST inj No 5⁄ 60 yes given
34 Ravi 54 M 83832 No 6 ⁄36 6 ⁄9 SICS WITH PCIOL Uveitis 4 to 6 Gp A No yes 6 ⁄6 no no
35 Pothumponnu 66 F 83856 No 6 ⁄60 6⁄ 12 ECCE WITH PCIOL Uveitis 4 to 6 GpA No yes 6 ⁄9 no no
36 Jayachandran 51 M 83934 No 6⁄ 24 6⁄ 12 PHACO WITH PCIOL Uveitis 11 to 24 Gp A No yes 6⁄ 6 no no
37 Selvam 64 M 83989 Both 6⁄ 60 6⁄ 36 SICS WITH PCIOL PCR AND VL 4 to 6 Gp B Rpt PST No 6 ⁄36 no no
38 Raasathi 54 F 84134 No 6⁄ 24 6 ⁄12 PHACO WITH PCIOL Uveitis 11 to 24 GpA PST inj yes 6⁄ 6 no no
39 Palanisamy 62 M 84216 No 6 ⁄60 6 ⁄24 SICS WITH PCIOL PCR AND VL 4 to 6 Gp B Rpt PST No 6 ⁄24 no no
40 Radhakrishnan 48 M 84278 No 6 ⁄36 6⁄ 9 PHACO WITH PCIOL Vitritis >24 Gp A No yes 6⁄ 9 no no

